Publication: Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants
dc.contributor.author | Irving Sivin | en_US |
dc.contributor.author | Pekka Lähteenmäki | en_US |
dc.contributor.author | Sirpa Ranta | en_US |
dc.contributor.author | Philip Darney | en_US |
dc.contributor.author | Cindy Klaisle | en_US |
dc.contributor.author | Livia Wan | en_US |
dc.contributor.author | Daniel R. Mishell | en_US |
dc.contributor.author | Maria Lacarra | en_US |
dc.contributor.author | Osborn A.C. Viegas | en_US |
dc.contributor.author | Prapas Bilhareus | en_US |
dc.contributor.author | Suporn Koetsawang | en_US |
dc.contributor.author | Manee Piya-Anant | en_US |
dc.contributor.author | Soledad Diaz | en_US |
dc.contributor.author | Margarita Pavez | en_US |
dc.contributor.author | Francisco Alvarez | en_US |
dc.contributor.author | Vivian Brache | en_US |
dc.contributor.author | Katherine LaGuardia | en_US |
dc.contributor.author | Harold Nash | en_US |
dc.contributor.author | Janet Stern | en_US |
dc.contributor.other | Population Council Headquarters | en_US |
dc.contributor.other | Helsingin Yliopisto | en_US |
dc.contributor.other | Bellevue Hospital Center | en_US |
dc.contributor.other | Keck School of Medicine of USC | en_US |
dc.contributor.other | National University of Singapore | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Instituto Chileno de Medicina Reproductiva | en_US |
dc.contributor.other | Asoc. Pro Bienstar de la Familia | en_US |
dc.contributor.other | Weill Graduate School of Medical Sciences | en_US |
dc.date.accessioned | 2018-07-04T07:51:28Z | |
dc.date.available | 2018-07-04T07:51:28Z | |
dc.date.issued | 1997-02-01 | en_US |
dc.description.abstract | In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant®-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml. | en_US |
dc.identifier.citation | Contraception. Vol.55, No.2 (1997), 81-85 | en_US |
dc.identifier.doi | 10.1016/S0010-7824(96)00276-4 | en_US |
dc.identifier.issn | 00107824 | en_US |
dc.identifier.other | 2-s2.0-0343683454 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/18168 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0343683454&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0343683454&origin=inward | en_US |